AEON Biopharma investor reports 13% stake

AEON Biopharma, Inc. (AEON) received a Schedule 13G reporting that Timothy P. Lynch beneficially owns 6,500,000 shares of its Class A common stock.

Rhea-AI Filing Summary

AEON Biopharma, Inc. (AEON) received a Schedule 13G reporting that Timothy P. Lynch beneficially owns 6,500,000 shares of its Class A common stock. This represents 13.0% of the class, based on 49,882,790 shares outstanding as of August 6, 2026.

Lynch reports sole voting and dispositive power over all 6,500,000 shares, with no shared power. The filing notes additional prefunded warrants for 1,000,000 shares and milestone warrants for 6,000,000 shares are excluded from beneficial ownership because a 4.99% Beneficial Ownership Limitation currently prevents their exercise.

Key Figures

Shares beneficially owned: 6,500,000 shares Percent of class: 13.0% Shares outstanding: 49,882,790 shares +5 more

8 metrics

Shares beneficially owned 6,500,000 shares Class A common stock beneficially owned by Timothy P. Lynch

Percent of class 13.0% Portion of AEON Class A common stock reported as beneficially owned

Shares outstanding 49,882,790 shares Class A common stock outstanding as of August 6, 2026

Sole voting power 6,500,000 shares Shares over which Lynch has sole power to vote or direct the vote

Sole dispositive power 6,500,000 shares Shares over which Lynch has sole power to dispose or direct disposition

Prefunded warrants 1,000,000 shares Shares underlying prefunded warrants excluded from beneficial ownership

Milestone warrants 6,000,000 shares Shares underlying milestone warrants excluded from beneficial ownership

Beneficial Ownership Limitation 4.99% Ownership cap that prevents exercise of the reported warrants

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, prefunded warrants, +2 more

6 terms

beneficially owned financial

"Amount beneficially owned: 6,500,000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 6,500,000.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 6,500,000.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

prefunded warrants financial

"exclude prefunded warrants to purchase 1,000,000 shares of Class A"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

milestone warrants financial

"and milestone warrants to purchase 6,000,000 shares of Class A"

Milestone warrants are rights that let holders buy a company’s stock only if specific goals—such as regulatory approvals, sales targets, or project completions—are met. Think of them as a coupon that only becomes usable when the company hits agreed checkpoints; they matter to investors because they create contingent value and potential share dilution, and they signal which outcomes the company and its backers consider most important.

Beneficial Ownership Limitation financial

"would beneficially own more than 4.99% of the outstanding shares"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of AEON (AEON) does Timothy P. Lynch report owning?

Timothy P. Lynch reports beneficial ownership of 13.0% of AEON Biopharma, Inc.’s Class A common stock, representing 6,500,000 shares based on 49,882,790 shares outstanding as of August 6, 2026.

How many AEON (AEON) shares does Timothy P. Lynch control?

Timothy P. Lynch reports beneficial ownership of 6,500,000 shares of AEON Class A common stock, with sole voting power and sole dispositive power over all of those shares and no shared voting or dispositive power.

What warrants related to AEON (AEON) are excluded from Timothy P. Lynch’s 13G?

The 13G states that Lynch’s reported holdings exclude prefunded warrants for 1,000,000 shares and milestone warrants for 6,000,000 shares of AEON Class A common stock, which are not currently exercisable due to a beneficial ownership limitation.

Why can’t Timothy P. Lynch currently exercise his AEON (AEON) warrants?

The filing explains the warrants may not be exercised if, after exercise, Lynch would beneficially own more than 4.99% of AEON’s outstanding Class A common stock. Because of this Beneficial Ownership Limitation, he cannot currently exercise any of the warrants.

What share count does the AEON (AEON) Schedule 13G use to calculate ownership?

The ownership percentages are based on 49,882,790 shares of AEON Class A common stock outstanding as of August 6, 2026, as reported by AEON in its Form 10-Q for the quarter ended June 30, 2026.

What is reported as Timothy P. Lynch’s voting and dispositive power in AEON (AEON)?

The Schedule 13G reports that Lynch has sole voting power over 6,500,000 shares and sole dispositive power over 6,500,000 shares, with 0 shares under shared voting or shared dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 07:44 PM Accepted by SEC EDGAR 08/21/2026 - 07:44 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AEON Biopharma, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

00791X209

(CUSIP Number)

08/19/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00791X209

1

Names of Reporting Persons

Timothy P. Lynch

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,500,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,500,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.0 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The securities reported herein exclude prefunded warrants to purchase 1,000,000 shares of Class A Common Stock and milestone warrants to purchase 6,000,000 shares of Class A Common Stock. Those warrants may not be exercised to the extent that, after giving effect to such exercise, the reporting person would beneficially own more than 4.99% of the outstanding shares of Class A Common Stock. As a result, the reporting person cannot currently exercise any of the warrants. The percentages reported in this Schedule 13G are based on 49,882,790 shares of Class A Common Stock outstanding as of August 6, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AEON Biopharma, Inc.
(b)	Address of issuer's principal executive offices: 130 VANTIS DRIVE, SUITE 170, ALISO VIEJO, CA, 92656
Item 2.
(a)	Name of person filing: Timothy P. Lynch
(b)	Address or principal business office or, if none, residence: 70 SW Century Dr, STE 100 PMB 1257 Bend, OR 97702
(c)	Citizenship: USA
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP Number(s): 00791X209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,500,000
(b)	Percent of class: 13.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6,500,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6,500,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Timothy P. Lynch

Signature:	/s/ Timothy P. Lynch
Name/Title:	Reporting person
Date:	08/21/2026